Moderate pharma sales rise is bright spot for J&J as devices and OTC slump
This article was originally published in Scrip
Executive Summary
Despite a slight 0.2% year-over-year dip in first quarter sales volume to $16.1 billion for the first three months of 2012 Johnson & Johnson is "off to a good start" for the year, considering new generic competition for two former blockbuster drugs, according to the New Brunswick, New Jersey-based company's chief financial officer.